A Psychiatric Times meta-analysis suggests anti-inflammatory treatments modestly improve depressive symptoms and anhedonia in adults with elevated CRP (≥2 mg/L)—supporting a precision-psychiatry lens for “inflammatory depression.” Effect sizes favored anti-inflammatories, though remission/response rates vs. placebo weren’t significantly different. Potent agents (e.g., TNF-α/IL-6 inhibitors) carry risks and need stronger RCT evidence.

A provocative new analysis published in Nature reveals that when large language models (LLMs) were subjected to simulated psychotherapy sessions, their responses exhibited patterns that resembled memories, fears, and emotional narratives — prompting concern among psychologists and AI researchers about what these outputs mean for the future of AI in mental health care.

When clinical work gets overloaded with templates, portals, and productivity targets, it’s easy for encounters to feel transactional. A recent Medscape feature poses a sharp question: are our bedside interactions building trust or merely checking boxes? The piece argues for reclaiming the human core of care—presence, curiosity, and meaning—without abandoning structure. For psychotherapy, where the therapeutic alliance is the treatment vehicle, these lessons are immediate and actionable.

Childhood emotional neglect (CEN) rarely looks dramatic. Instead of overt abuse, it’s the everyday absence of attunement—caregivers who miss, minimize, or dismiss a child’s feelings. As the Psychology Today article explains, those “non-events” leave a deep imprint that often reappears in adult romantic relationships as confusion about needs, difficulty trusting closeness, and repeated conflict cycles.

NRx Pharmaceuticals (NASDAQ: NRXP) and neurocare Group AG announced a nationwide partnership to offer integrated neuroplastic therapy for depression, PTSD, and other serious mental health conditions. The program will connect neurocare’s clinic footprint and 400+ Apollo® TMS devices with HOPE Therapeutics clinics, unify treatment protocols and training, and pursue payer contracts to make care available “within driving distance of any American home” by year-end 2026.

Medscape’s commentary, “No Pill for the Human Condition,” makes a timely, clear point: drugs can lower symptom burden, but they cannot eliminate the deeply human pain of loss, isolation, shame, and meaning-disruption—what the piece calls psychache. The article urges clinicians and systems to name and measure psychache explicitly, then pair medication (when indicated) with psychotherapy that restores agency, connection, and purpose. In short: pharmacology can open a door; psychotherapy helps patients walk through it.

On August 8, 2025, Illinois became the first U.S. state to formally restrict AI from delivering therapeutic or diagnostic services under the Wellness and Oversight for Psychological Resources (WOPR) Act. By banning unlicensed AI “therapists” and setting fines up to $10,000, the law draws a critical distinction between wellness tools and clinical practice—ensuring patients receive guidance only from qualified professionals. 

What the WOPR Act Does